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ABSTRACT  
Biobanks are useful platforms to build bridges between basic, translational and clinical research 
and clinical care. They are repositories of high-quality human biological samples ideal for 
evaluating their histological characteristics and also their genome, transcriptome and proteome. 
The Spanish Renal Research Network Biobank contains more than 76,500 well-preserved 
frozen samples of a wide variety of kidney diseases, collected from 5,450 patients seen over 70 
nephrology services throughout the Spanish territory. Objective: to determine and to report the 
results of the quality control of samples and processes conducted in our biobank, implemented 
in accordance with the requirements of ISO 9001:2008 international standard. Study design: 
two types of quality controls were performed: i) systematic i.e. measurement of viable 
Peripheral Blood Mononuclear Cells (PBMC) obtained and purity of nucleic acids and ii) ad-
hoc: i.e. viability of thawed PBMC, DNA extraction process reproducibility and the integrity 
and functionality of nucleic acids, implemented on a routine basis. Methods and Results: 
PBMC isolation by Ficoll yielded reproducible results and their cryopreserved viability was 
greater than 90%. Acceptable A260/A280 ratios were obtained for the vast majority of the DNA 
(n=2328) and RNA (n=78) analyzed. DNA integrity was demonstrated by agarose gels and by 
β-globulin gene PCR amplification of 1327 and 989 bp fragments. . DNA of acceptable quality 
had at least three bands of β-globulin amplified obtained (n=26/30). RNA Integrity Number 
(RIN) determination obtained RIN numbers ≥ 7 (n=87/96). The ampliafiability of nucleic acids 
was confirmed by qPCR and RT-qPCR of β-actin and GAPDH genes. Long storage or delay 
processing time did not affect the quality of the samples analyzed. The processes of DNA 
extraction also yielded reproducible results. Conclusions: these results clearly indicate that our 
PBMC, DNA and RNA stored samples meet the required quality standards to be used for 
biomedical research, ensuring their long-term preservation.  
 
KEY WORDS: biobank, ISO 9001:2008, quality control, chronic kidney disease 
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INTRODUCTION 
Currently, the knowledge of the complex etiology of diseases constitutes a challenge, given the 
multitude of factors that may influence their development, which include genetic predisposition, 
lifestyle and environmental conditions. Knowing and understanding these complex interactions 
are critical to facilitate researchers’ access to a large number of well-documented biological 
samples, selected according to scientific criteria well suited to the research to be developed and 
that meet the quality standards required for analysis using new high-performance technologies. 
In this context, it is highly useful to build easily accessible infrastructure that enables rapid 
experimental demonstration of a hypothesis or the verification of a simulation model. A biobank 
is a facility which processes, stores, archives and distributes human samples and their associated 
clinical data, which are used to promote the advance of biomedical research. Well-preserved 
frozen samples are ideal for evaluating the genome, the transcriptome, the proteome and the 
metabolome1-3. When the molecular analysis of nucleic acids, proteins, and metabolites is being 
conducted, the quality of the starting samples obtained from these repositories has to be taken 
into consideration, since factors such as degradation, the presence of impurities, and enzyme 
inhibitors may have a significant impact on the results obtained4-9. Hence, it is necessary to 
ensure the adequacy of samples available for mass screening analysis used at current 
translational research. These rigorous demands as well as the long-term storage of samples 
stored in biobanks require the implementation of quality controls; these controls will depend on 
the type of sample stored5-14.  
At present, there are many biobanks that conduct quality controls; and there is some consensus 
on the specific type of quality control to be performed on each different sample. In this regard, 
for RNA and DNA samples, it is important to check their integrity and purity1-4; 6-12. For RNA 
samples, the ratio of absorbance at 260nm and 280nm is used to assess their purity15. To 
determine RNA sample integrity, two major ribosomal bands, 28s and 18s, should be observed 
in agarose gel or microchip electrophoresis16, the RNA Integrity Number (RIN) can be 
calculated1, and genes can be amplified by RT-PCR2. The purity of DNA samples is assessed in 
the same way as the RNA samples15, whereas its integrity can be obtained by observing the 
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presence of a band of high molecular weight in agarose gels without degradation and verified by 
PCR gene amplification1. For serum samples, specific biomarkers (i.e. transferrin receptor, 
ascorbic acid, K+, soluble CD40L (sCD40L), adrenocorticotrophic hormone (ACTH), vascular 
endothelial growth factor (VEGF) and the matrix metalloproteinase-7 (MMP-7))17 are 
particularly unstable and sensitive to pre-analytical variations and the ISBER Biospecimen 
Science Working Group have recently published the assays that can be used to assess such 
variation for which there is a consensus18. Finally, to control human PBMCs (Peripheral Blood 
Mononuclear Cells) cryopreserved in DMSO, cell viability is assessed after thawing2,13, with 
viability values greater than 80%19-20. Also, the HIV/AIDS Network Coordination -HANC- 
proposes the assessment of PBMC performance for quality control, i.e. the number of PBMCs 
obtained per milliliter of collected blood21. In addition, granulocytes (CD15+), which 
contaminate PBMC isolates after prolonged blood storage, should not be present in the PBMC 
interphase22. 
The REDinREN (Spanish Renal Research Network) Biobank, founded in 2007, hosts a 
collection of samples designed for biomedical research of kidney disease and it is organized as a 
technical unit with quality, order and purpose criteria. Its mission is to contribute to the advance 
of scientific knowledge of kidney failure within the concerted action of REDinREN, affiliated 
with the Instituto de Salud Carlos III (RD6/0016/0002). Their activities are conducted in 
accordance with 14/2007 Law on Spanish Biomedical Research23 and 1716/2011 Royal 
Decree24, as well as ISBER’s-International Society for Biological and Environmental 
Repositories-Best Practice Guide4. Since its inception, this biobank complies with other national 
laws, such as: Personal Data Protection Act25 and the regulations for the transport of biological 
substances26. The achievements of REDinREN Biobank include its significant ongoing growth 
in the number and type of samples27 received from all over Spain, the implementation of ISO 
9001:2008 international standard and the accreditation of its registration in the National Spanish 
Registry of Biobanks. The implementation of ISO 9001:2008 standard has improved the 
efficiency of our biobank, by saving process execution time (by 70%), increasing the number of 
samples processed (by 200%) and implementing quality controls of the sample itself and of the 
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processes carried out28. Specifically, we confirmed the improvement (by 25%) in the effective 
management of samples transferred to research centers, one of the main processes of our 
biobank, resulting in higher customer satisfaction. The large increase in the number of samples 
processed was directly related to the improvement of the process28. In this work, we present the 
result of quality controls performed in accordance with the requirements of the above-
mentioned standard, reporting the data resulting from the quality control of samples and 
processes. For the former, the samples analyzed were: DNA and RNA, and the viability of 
Peripheral Blood Mononuclear Cell (PBMC) cryopreserved in DMSO. For the latter, the 
process analyzed was the DNA isolation. The quality control results presented here permit us to 
assure that PBMC, DNA and RNA samples stored and processed at our biobank can serve as 
suitable sources of material for biomedical research on kidney disease. 
 
MATERIAL AND METHODS 
 
1 Ethical approval. 
The Biobank Project was approved by the Ethical Committee of Spanish Renal Research 
Network’s Biobank (National Register Number 0000931). Informed consent was obtained in 
writing from all patients after institutional approval. The studies conformed to the standards set 
by the latest revision of The Code of Ethics of the World Medical Association (Declaration of 
Helsinki) for experiments involving humans. 
 
2 Sample Type and collection. 
The samples chosen for this work were selected from more than 76,500 stored in the 
REDinREN Biobank, obtained from 5,450 patients with chronic kidney disease coming from 
more than 70 services of Nephrology and dialysis centers from all over the Spanish territory. At 
present, the biobank holds samples of different types: serum, plasma, proteins, urine, blood, 
DNA and RNA (preserved at -80°C) and viable peripheral blood mononuclear cells (PBMC, 
cryopreserved at -190°C). Blood specimens were collected from renal patients into 5 different 
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tubes (8 milliliters each); 1 EDTA tube for plasma, 2 EDTA tubes for PBMC isolation (for 
DNA and protein extraction and viable cryopreserved cells), 1 tube for serum and 1 PAXgene 
tube (PAXgene Blood RNA Tubes, Qiagen, New Jersey, USA) for total RNA extraction21. The 
specimens were collected by personnel trained at each participating center from the antecubital 
area of the arm by drawing venous blood using sterile technique, transported in appropriate 
temperature conditions, at 4ºC, in accordance with the present law, delivered to the biobank in 
less than 24 hours, according to a programmed schedule with the participating center (maximum 
ten patients at day). Once the samples arrive, the biobank staff starts to process them without 
delay. The range of delay between the sample extraction and their processing by the biobank 
was 2 to 24 hours.  
 
3 Implementation of quality controls. 
The quality controls currently performed in the biobank are of two types: 
3.1 Systematic: i.e. measurement of number of viable PBMC that were isolated from peripheral 
blood using Ficoll (n=2724) and purity of nucleic acids (DNA n=2328, RNA n=78)  
3.2 Ad-hoc: i.e. viability of thawed PBMC (n=10), extraction of DNA from three pools of 
PBMC to test the DNA extraction process reproducibility (n=15) and the integrity and 
functionality of nucleic acids (DNA and RNA agarose gel n=48, DNA β-globin amplification 
n= 30, RNA RIN n=96, DNA and RNA functionality n=30). 
These quality controls have been implemented on a routine basis (with established frequency). 
(See Table 1) 
3.2.1 Sample selection criteria 
The sample selection criteria for ad-hoc quality controls were the following ones: i) To analyze 
PBMC post-thawed viability, two selection criteria were used: samples must have been stored 
for at least 3 years and must have at least 5 cryovials stored from the same specimen. Two 
samples, each from a different year, were randomly selected for each analysis. This control was 
performed semi-annually, having started in 2013. ii) To prepare the 3 pools of PBMC, each one 
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was made on a different day with cells from 12 patients with surplus (once all relevant samples 
were stored, including 5 PBMC samples cryopreserved at -190ºC) of at least 8 x 106 cells to 
pool. iii) To analyze DNA integrity and functionality, the sample selection criterion used was a 
previous DNA extraction, with an A260/A280 ratio of 1.8-2.1. Six stored samples from 
different years, covering the eight-year collection period, were randomly selected for each 
analysis. iv) To analyze RNA integrity and functionality, the selection criterion used was a 
previous RNA extraction. Six samples for agarose gel and functionality and twelve samples for 
RIN were randomly selected for their respective analyses; samples stored in different years, 
covering the eight-year collection period, were used for each test. For i) to iv) the controls had 
been performed every four months, having started in 2013 or 2014 (see Table 1). 
Table 1 summarizes, for each type of sample being tested, its implementation year, frequency, 
number of samples analyzed at each time, number of tests performed and total number of 
samples tested so far in the Biobank of REDinREN.  
The number of samples of each type was approved by AENOR (Spanish Association for 
Standardization and Certification: “Asociación Española de Normalización y Certificación”) in 
2013, when the ISO 9001:2008 norm was certified, and in the first and second audit carried out 
in 2014 and 2015. 
 
4 Evaluation of PBMC isolation and storage quality. 
4.1 PBMCs Isolation and number of viable cells obtained. 
Whole blood (from the 2 tubes anti-coagulated with EDTA) was diluted to 50% with sterile 
saline solution (PBS -Phosphate Buffered Saline Solution, Thermo Fisher Scientific Inc., 
Waltham, MA, USA). 10 ml of diluted blood was layered over 20 ml of the Ficoll gradient 
(Lymphocyte Isolation Solution, commercialRafer, Zaragoza, Spain). Gradients were 
centrifuged at 400 × g for 30 min at room temperature in a swinging-bucket rotor without the 
brake applied. The PBMC interface was carefully removed by pipetting. The isolated 
lymphocytes were washed in PBS by centrifugation at 200 × g for 10 min and the number of 
viable PBMC obtained was evaluated in a systematic way. For this propose, isolated 
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lymphocytes were counted and their viability determined by Trypan Blue exclusion, using a 
Countess® Automated Cell Counter (Life Technologies Ltd., Paisley, UK), as previously 
described29. Cell pellet samples were aliquoted in 6 cryovials, each containing 4 x 106 cells and 
stored at -80°C. Three samples were kept for automated DNA extraction and the other three 
were kept for protein extraction. Extractions are performed only when requested by a 
researcher. When PBMCs viability exceeded 80%, all the remaining cells were cryopreserved in 
liquid nitrogen at -190°C (8 x 106 cells per sample placed into a cryovial), in 20% Fetal Bovine 
Serum (FBS) supplemented medium with 10% dimethylsulfoxide (DMSO) (Sigma Aldrich, St. 
Louis, MO, USA).To freeze them, cryovials containing PBMCs were placed in a Mr. Frosty 
Freezing Container (Nalgene, Thermo Fisher Scientific Inc. ) filled with isopropanol precooled 
at 4ºC, cooled slowly overnight to –80ºC and then transferred to liquid nitrogen. 
 
4.2 Analysis of thawed PBMC viability. 
The PBMC stored at -190ºC were thawed and cultured in 1640 RPMI medium (LONZA, Basel, 
Switzerland) supplemented with 10% FBS, L-glutamine (1 mM), penicillin (0.66 µg/ml) and 
streptomycin sulfate (60 µg/ml), at 37°C in 5% CO2 atmosphere. No proliferative stimulus was 
added to the medium. Cell viability was measured by Trypan Blue exclusion at the time of 
thawing (time 0) and every 24 hours during the following 14 days. Each measurement for each 
day was performed in triplicates. 
 
5 Analysis of total DNA extraction and DNA purity, integrity and functionality.  
5.1 DNA extraction, concentration and purity.  
The total DNA of the samples requested by researchers was extracted from PBMC pellets stored 
at -80°C. Automated extraction was performed using QIAamp DNA Mini kit (Qiagen) 
according to the manufacturer’s standard protocol. DNA extraction was performed using a 
robotic workstation for automated purification of nucleic acid: QIAcube (Qiagen). DNA was 
quantified using a spectrophotometer (NanoPHotometer, Implen, Munich, Germany). DNA 
concentration was determined by measuring the absorbance at 260nm. DNA purity was 
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determined by the A260/A280 ratio; the A260/A280 ratio between 1.8 and 2.1 being considered 
acceptable3.  
 
5.2 DNA integrity. 
DNA integrity analysis by denaturing agarose gel electrophoresis on 1% has been performed 
using the intact DNA untreated or treated with DNAse (27 Kunitz units, 15 min, 20-30°C) or 
denatured by heating (100°C, 15 min.), as specific DNA degradation negative integrity controls. 
The integrity of DNA retrieved was also assessed by PCR amplification of four different 
amplicons of the housekeeping β-globulin gene (268, 536, 989 and 1327 base pair). The PCR 
amplification was performed using the DNA polymerase enzyme (Biotools, Madrid, Spain), 
with the primers shown in Table 2. The PCR conditions were: initial denaturalization at 95° C 
for 3 min., followed by 40 denaturation cycles at 95°C for 1 min., annealing at 55° C for 1 min., 
72° C extension for 1.5 min., and a final extension at 72°C for 5 min. The PCR products 
obtained were analyzed by gel electrophoresis on a 1% agarose gel. Gels were stained with 
RedSafeTM, Nucleic Acid Staning Solution (20000x) (Promega, Madison, WI, USA). DNA of 
acceptable quality had at least three bands of ß-globulin amplified from DNA1.  
 
5.3 DNA functionality by quantitative PCR.  
Endogenous β-actin and GAPDH genes were amplified by qPCR with LC FastStart DNA 
Master SYBR Green I Kit (Roche, Mannhein, Germany), in direct DNA (250ng in each 
reaction, carried out in triplicate) samples. The pairs of primers used were: human GAPDH: 5´-
TCC ACT GGC GTC TTC ACC- 3´ (forward) and human GAPDH: 5´-GGC AGA GAT GAC 
CCT TTT- 3´ (reverse); human β-actin: 5´-TCA CCC ACA CTG TGC CCA TCT ACG A- 3´ 
(forward) and human β-actin: 5´-CAG CGG AAC CGC TCA TTG CCA ATG G- 3´(reverse). 
qPCR was performed employing the 7500 Fast real-time PCR System and 7500 Fast sequence 
detection software v1.3.1 (Applied Biosystems, CA, USA) as per the following cycling 
conditions: 50ºC for 2min and 95ºC for 10 min, followed by 45 cycles of 95ºC for 15 sec, and 
60ºC for 1min. 
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6 Analysis of total RNA extraction and RNA purity, integrity and functionality. 
6.1 RNA extraction, concentration and purity.  
Total RNA extraction was conducted using peripheral blood samples stored in PAXgene tubes 
(PAXgene Blood RNA Tubes, Qiagen), collected from each participating center. At the 
biobank, automated extraction was performed using the PAXgene® Blood RNA Kit (Qiagen), 
according to the manufacturer's instructions. RNA extraction was performed using a robotic 
workstation for automated purification of nucleic acid: QIAcube. RNA samples were preserved 
at -80°C. When samples were requested, RNA concentrations were systematically measured 
with a spectrophotometer (NanoPHotometer, Implen). RNA purity was also systematically 
determined by measuring the A260/A280 ratio. 
 
6.2 RNA integrity. 
The RNA integrity was analyzed by determining the RNA Integrity Number (RIN), using the 
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), in the Department of 
Genomics of the PCM Foundation, Universidad Autonoma de Madrid, Spain. The RIN, an 
algorithm based on a selection of features resulting from data obtained from an 
electropherogram of a given sample30. RIN is a scale of RNA quality with RIN 1 denoting 
completely degraded RNA, RIN 10 denoting completely intact RNA and a RIN 7 value is 
regarded as a threshold above which samples are suitable for most applications1,30-31.  
 
6.3 RNA functionality by quantitative RT-PCR.   
cDNA was obtained from RNA (2µg) by using the High Capacity cDNA Reverse 
Transcription Kit. Then, endogenous β-actin and GAPDH genes were amplified by qPCR in 
cDNA (250ng in each reaction, carried out in triplicate), as described for DNA, using the same 
probes. As a sample selection criterion, RNA had been previously extracted and the sample 
number and collection period were the same as for DNA. 
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7 Quality control of the DNA extraction process. 
After isolation, the selected PBMC were pooled, stored in cryovials (4 x 106 cells) and frozen at 
-80ºC until their use. DNA concentration and purity analysis on the 3 different PBMC pools was 
conducted each 4 months as described and the coefficients of variation (CV), calculated as CV= 
(standard deviation (SD)/mean)*100, obtained from the different measures performed to the 
same pool were calculated.  
 
8 Statistical Methods 
Descriptive statistics were used to show the data concerning the different distribution values. 
The normality of the distributions was tested by the Kolmogorov-Smirnov test. For normal 
distributions, to compare the delay in processing time values for the PBMC yields and the DNA 
ratios, the Student’s paired t-test was performed. For normal distributions, to compare the 
differences among the time of storage of the samples, ANOVA was used with no additional 
tests. The normal distributions were represented as mean ± SD. For non-normal distributions, 
assigning statistical significance to the differences between the storage times and the delay to 
processing times, the Kruskal-Wallis test or Mann-Whitney U test were used. The non-normal 
distributions were represented as median plus an interquartile range (IQR). Statistical 
significance was set at p<0.05. 
 
RESULTS 
Quality control of viable PBMC isolation  
PBMC isolation was evaluated by examining the number of viable cells obtained per milliliter 
of whole blood. The mean of viable PBMC obtained remained stable without significant 
differences from year 2010 to 2015 (p = 0.3637) (Figure 1). The mean total number of viable 
cells isolated was 3.17 ± 1.12 x 106 PBMC/ml of blood from 2,724 specimens analyzed, which 
were the ones admitted to the biobank in those years (year 2010 (n = 181), 2011 (n = 868), 2012 
(n = 902), 2013 (n = 359), 2014 (n = 255) and 2015 (n = 159). Moreover, although viable 
PBMC mean number obtained in samples with less than 4 h pre-centrifugation delay was higher 
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when compared to the 24 h delay group, the difference was not statistically significant (mean 4 
h: 3.36 ± 1.12, n=523; mean 24 h: 3.01 ± 1.18, n=2,201. p = 0.469, t-test). 
 
Quality control of recovery and viability of Peripheral Blood Mononuclear Cells stored at 
-190ºC. 
Figure 2 represents the viability of the ten thawed samples. As shown on day 0, the viability was 
96.5% (IQR 94.75-97.25), which indicates that the freezing process did not affect cell viability. 
Values above the horizontal line, which indicates a cell viability of 80% -minimum acceptable 
viability threshold-, were recorded on days 1 to 14. At the 14th day, viability was observed to 
descend to 80%. The median percentage of post-cryopreservation viable cells recovery of these 
ten samples of PBMC was 84.5% (IQR 78.4–100.0). When we evaluated the percentage of 
PBMCs that were still viable after 14 days in culture, and compared it between aliquots of 
PBMCs that had been in storage for the longest period of time (years 2007-2009; 85%, IQR 83-
87.5) and the shortest period of time (years 2010-2012; 83%, IQR 80.5-83) the difference fell 
just short of being statistically significant (p = 0.056, Mann-Whitney U test). This analysis 
indicates that long-term storage time may  not affect the cryopreserved PBMC viability. In 
addition, the percentage of live cells after 14 days post-thawing was not significantly different 
between the samples which were collected and processed with a delay of less than 4 h and those 
of less than 24 h (p = 0.383, Mann-Whitney U test). 
 
Quality control of DNA samples stored at -80ºC. 
To evaluate the quality of DNA samples, we analyzed three parameters: purity, integrity and 
functionality, measured as gene amplification ability. Figure 3A shows the purity of the DNA 
isolated from 2,328 samples analyzed, which are the total number extracted to date, grouped by 
year of storage. The mean A260/A280 ratio value was 2.05 ± 0.14and the storage time is not 
affecting the DNA purity (p = 0.063). In addition, the mean DNA ratio was not significantly 
different between the samples which were collected and processed with a delay of less than 4 h 
and those of less than 24 h (mean 4 h: 2.025 ± 0.21, n=498; mean 24 h: 2.059 ± 0.18, n=1,830. 
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p=0.338, t-test). Figure 3B shows the DNA integrity in two representative samples of the 48 
analyzed to date, indicated by the presence of a single high-molecular weight band in the intact 
DNA (untreated), in comparison with negative controls after DNAse treatment and after being 
heated, with no band or a very diffuse band being observed in either of the latter two cases, as 
expected. We have found some partial degradation in the 4.2% of extracted DNA samples (2 of 
48 samples), following electrophoresis (Figure 3B, Sample 2). These data were completed with 
the PCR amplification of four β-globulin gene fragments. Figure 3C shows four amplified 
fragments of a representative sample of the 30 analyzed to date, with sizes ranging from 268 to 
1327 bp, which correspond to high quality DNA (without being fragmented). DNA of 
acceptable quality with at least three bands of β-globulin amplified was obtained in 26 of the 30 
samples analyzed to date (76.7% (n=23) four bands; 10% (n=3) three bands; 13.3% (n=4), two 
bands). Finally, DNA retrieved functionality was assessed by β-actin and GAPDH constitutive 
genes amplification by qPCR (Figure 3D and E). The median Ct values (number of cycles 
required to reach the detection threshold) of the 30 samples studied to date were 19.75 (IQR 
19.25-21.32) for β-actin and 22.37 (IQR 21.91-23.18) for GAPDH, which demonstrates that it 
can be used for genome analysis. As observed, storage time is not affecting DNA functionality 
(p=0.239 for β-actin and p=0.969 for GAPDH, Kruskal-Wallis test). In addition, the median Ct 
value was not significantly different between the samples which were collected and processed 
with a delay of less than 4 h and those of less than 24 h (p=0.440 for β-actin and p=0.134 for 
GAPDH, Mann-Whitney U test). 
 
Quality control of RNA samples stored at -80ºC. 
The quality control of stored RNA samples was likewise performed by assessing the following 
parameters: purity, integrity and amplification ability. Figure 4A shows the RNA purity of the 
78 samples extracted to date, grouped by year of storage. The median A260/A280 ratio value 
was 2.04 (IQR 1.96-2.07) and, as observed, storage time is not affecting RNA purity (p=0.089, 
Kruskal-Wallis test). Moreover, the median RNA ratio was not significantly different between 
the samples which were collected and processed with a delay of less than 4 h and those of less 
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than 24 h (p=0.374, Mann-Whitney U test). The RNA integrity was determined by the 
assessment of RIN. As shown in Figure 4B (Left Panel), the mean RIN value for 2007-2015 
period was between 7.3 and 9.1 (8.19 ± 0.92); which demonstrates that long-term storage time is 
not affecting the integrity of stored RNA in the 96 samples analyzed to date (p=0.092). Very 
good RIN numbers ≥ 7 were obtained in 87 of 96 samples. Finally, Figure 4C and D show β-
actin and GAPDH constitutive genes amplified by RT-qPCR. The median RIN value was not 
significantly different between the samples processed with a delay of less than 4 h and those of 
less than 24 h (p=0.079, Mann-Whitney U test). The median Ct values of the 30 samples studied 
to date were 20.04 (IQR 18.2-20.86) for β-actin and 21.0 (IQR 19.0-22.71) for GAPDH. These 
results confirm that these samples can be used for gene expression analysis. Moreover, it can be 
observed that storage time is not affecting RNA functionality (p=0.639 for β-actin and p=0.773 
for GAPDH, Kruskal-Wallis test). Finally, the median Ct value was not significantly different 
between the samples which were collected and processed with a delay of less than 4 h and those 
of less than 24 h (p=0.477 for β-actin and P=0.373 for GAPDH, Mann-Whitney U test). 
 
Quality control of DNA isolation processes. 
Finally, we performed the quality control of one of the most widely used processes, which is 
routinely carried out in the biobank. We assessed DNA isolation process by using 3 PBMC 
pools. Table 3 shows the mean concentration and purity values of the different measures 
performed to the same pool, and the CV of the measurements obtained, which demonstrates the 
reproducibility of the process. The lows CV for the ratio, especially as an indicator of the purity 
of DNA retrieved are particularly notable. 
 
DISCUSSION  
The aim of the present study was to determine and to present the results of the quality controls 
performed on the PBMC, DNA and RNA samples stored in the REDinREN Biobank, 
implemented according to ISO 9001:2008 standard, including quality controls of samples and 
processes. The results indicate that these samples obtained and preserved in this biobank have 
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the suitable quality and reproducibility to be used in biomedical research, using both classic 
analysis methodology and new high performance technology. 
First, the high number of viable PBMC obtained largely depends on the effective isolation from 
whole blood samples using the Ficoll method29. The results of PBMC isolation carried out at 
this biobank indicate an excellent quality, unaffected by the year when the process was 
performed or the number of samples processed. 
Moreover, the quality control of cryopreserved cells yields good levels of PBMC post-thaw 
viability; which guarantees that the freezing, cryopreservation and thawing process is being 
developed in a correct way. Efficient cryopreservation of cells offers many advantages to the 
research community32. This technique makes it possible that samples from the same donor 
banked over time can be processed simultaneously, allowing greater inter- and intra-laboratory 
control and reducing costs. It was previously shown that the viability of cryopreserved PBMCs 
has tremendous effects on the results of functional assays32, so that at least 80% viability is 
necessary to generate conclusive responses to antigens and mitogens. These PBMC can also be 
efficiently used for immunomagnetic separation of cells, cytokine production and flow 
cytometer analysis33-34.  
The limit of the length of time a PBMC sample can be stored in a biobank has not yet been 
determined, although numerous quality control studies approach this analysis on different types 
of samples stored13,19. In this study, samples are chosen at random from different years of 
storage. When we compared the percentage of PBMCs that were still viable after 14 days in 
culture, the analysis indicates that long-term storage may not affect the PBMC viability. We 
observed slightly higher viability values of the PBMCs that had been storage for a longer period 
of time. The almost statistically significant difference may be caused by the increased number 
of samples processed (deposited or transferred) during the more recent years studied. Due to the 
low number of samples analyzed, this result could be confirmed with a larger set of samples. 
We have now improved the process, protocols and staff training, with the changes that we 
performed during achievement of the ISO 9001:2008 standard implementation. These 
observations are of special importance for the long-term future of the REDinREN Biobank since 
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one of its objectives is to utilize biospecimens associated with clinical data to design and 
perform prospective studies.  
Moreover, it has been shown that time from venipuncture to PBMC isolation and 
cryopreservation may affect the cell quantity, recovery, viability, white blood cells 
subpopulation distribution, gene expression, and lymphoblastoid cell lines transformation35and 
also have impact in the viability and performance of T cells in downstream immunological 
assays36-37 and in the cytotoxic activity of natural killer cells38. In addition, it has also been 
shown that a 24-h delay between blood collection and processing, especially at 4ºC, 
significantly increases granulocyte contamination, which may inhibit T cell function22. Due to 
these findings, some authors recommend the processing of blood samples for PBMC isolation 
within shorter time periods (e.g. 8 hours)22,35-40. At that time, our biobank was not able to assess 
potential granulocyte contamination of the PBMC isolates.  However, in the present study, we 
analyzed samples from a wide range of processing delay (i.e. 2-24 hours) and we statistically 
compared the results between samples processed within less than 4 h or less than 24 h of 
collection. Although viable PBMC number obtained in samples with less than 4 h pre-
centrifugation delay was higher when compared to the 24 h delay group, the difference was not 
statistically significant. Likewise, statistical significance could not be assigned to any other 
comparisons we made between the two delay to processing cohorts.  Due to the relatively low 
number of samples analyzed, this result may be confirmed on a future larger set of samples and 
further studies may address the optimization of biospecimen processing methods to obtain high 
cell yields, the adequate subpopulation composition and improved cell viability for downstream 
applications in our stored samples.    
With regard to the analysis of samples of nucleic acids (DNA and RNA), the values obtained for 
the A260/A280 ratios indicate that both materials have an acceptable degree of purity, suitable 
for most applications8-9,41. The absorbance A260/A280 ratios of most samples were ranged 
between 1.8 and 2.1, which indicates that both nucleic acids obtained reach high purity levels. 
In addition, DNA and RNA A260/A280 ratios values did not show a significant difference 
related to stored year, which confirms long storage time does not affect their quality.  
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Indeed, the vast majority of the samples analyzed presented good ratios, within normal values42-
43, with a small percentage of samples (9.4% for DNA and 6.1% for RNA) deviating from the 
acceptable range. In the case of DNA analysis, the normal range of the A260/A280 ratio is 
between 1.8 and 2.1. A ratio higher than 1.8 is generally accepted as an indicator of pure nucleic 
acids whereas ratios lower than 1.8 may indicate contamination by proteins or other 
contaminants that absorb at or near 280 nm, or may also be due to the effect of several solvents 
used during the extraction of nucleic acids3,42. On the other hand, co-eluting RNA can become a 
"contaminant" of unknown magnitude in a DNA extraction, leading to an overestimation of 
DNA yield44. An alternative solution could be to use spectrofluorometry (in addition to 
spectrophotometry) to quantify the nucleotides routinely.  In our protocol, we decided to do not 
include RNase digestion, because we do not want to cross-contaminate either our laboratory or 
the QIAcube. For this reason, the data presented here are an estimate of the DNA concentration. 
In addition, contamination of the sample of DNA with RNA does not impair subsequent use in 
the majority of downstream applications. However, the use of DNase digestion is mandatory in 
the case of RNA extraction to prevent erroneous amplifications. In RNA analysis, a A260/A280 
ratio higher than 1.8 is usually accepted as an indicator of a pure RNA, relatively free of 
proteins43. We have not been able to identify the cause of the unacceptable purity values 
observed in the samples mentioned above; however, they are within the expectable margin of 
errors when handling or transporting samples. In addition, we have implemented corrective 
actions for these non-conforming results (Table 4), which allowed a 10% reduction in the DNA 
or RNA samples deviated from the acceptable range. 
The absorbance readings give no indication related to the physical integrity (lack of 
fragmentation) of the sample. A traditional method that can be used to assess nucleic acids 
integrity is agarose gel electrophoresis42, 45. In our results, the intact genomic DNA appears as a 
compact high molecular weight band with no or little low-molecular-weight material.  
Additionally, taking into account that the RNA is the most easily degradable component of 
biological samples, among other reasons, due to endogenous ribonucleases46, we assessed its 
integrity by calculating the RNA Integrity Number (RIN)31. In our study, only 9 of the 96 
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samples analyzed presented RIN values of less than 7; we have implemented corrective actions 
(Table 4).  
Our results do not show a decrease in RIN values with increasing storage time of the specimens 
in the biobank. Several studies have examined the RIN variation associated with storage time. 
In 2012, Bao et al. studied RNA from tissues collected over a 40-month period and obtained 
RIN values higher than 7 for all the samples analyzes47. Recently, Hebels et al. assessed RIN 
values in blood samples stored during a 4-19 year period at -80º C in Sweden, and during an 11-
19 year period in liquid nitrogen in Italy, and found no observable systematic adverse effects of 
storage time48. In 2013, Andreasson et al. analyzed RNA from 153 endocrine tissue samples 
stored for over almost three decades; the results suggest that RNA quality from tissues is not 
adversely affected by storage in well-monitored and maintained -80ºC freezers, which are 
capable of excellent preservation of high-quality RNA for decades. These findings challenge the 
arguments that claim that using liquid nitrogen for storage is always better and support the idea 
that -80ºC freezers are equally suitable for long-term preservation of tissue samples, with 
additional benefits resulting from environmental hazards11. In REDinREN Biobank, where RNA 
is preserved in freezers at -80ºC, the RIN number of samples stored is routinely assessed in 
order to ensure that the standards of quality required for stored material are uniform throughout 
the time.  
The utility of DNA or RNA retrieved from tissues for subsequent molecular applications can 
also be assessed by PCR amplification of a specific sequence. Nucleic acids with little or no 
PCR or RT-qPCR product indicate tissue degradation and poor quality6. Our results showed 
acceptable Ct values, which is a good indicator of the suitability of the material for subsequent 
use in biomedical research35.  
The quality control of the processes was also studied. The automated DNA extraction 
demonstrated the reproducibility and reliability of the standardized protocols and manipulations 
performed. The coefficient of variation obtained for A260/A280 ratio was very low, which is 
significant as this is indicative of the consistent purity of the DNA retrieved. Low coefficients 
of variation of DNA concentration also ensure intra-assay reproducibility of this method. 
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Up to the present, we have not performed either systematic or routine quality controls of plasma 
and serum samples stored in our biobank. So far, the scientific community has not reached a 
consensus to identify the best biomarkers to determine plasma and serum quality. The main 
problem is that it has not been possible to perform a specific test in a prospective way because 
the quality of plasma and serum is strongly linked to the research program. In this sense, 
biobanks, including our REDinREN Biobank, are a valuable tool, because they have 
competence to develop their own research, which enables them to optimize processes and find 
easy detection biomarkers to ensure the quality of all sample types. In addition, nine peer-
reviewed publications have resulted from samples in our biobank, which demonstrates that the 
samples are of quality that is amenable to downstream research49-57.     
Finally, it should be noted that, taking into account the special features of REDinREN Biobank, 
which contains samples from throughout Spain that must be transported to our center before 
being processed, our results support the idea that the construction of large sample cohorts from 
multiple centers can be carried out as long as strict controls are implemented over sample 
collection, transportation, reception and processing. Table 5 summarizes the difficulties related 
to multisite sample collection and the solutions implemented in REDinREN so as to better 
coordinate the process and the training of health technical personnel and to closely supervise all 
the partners involved in sample collection and delivery, including the establishment and 
implementation of common Technical Instructions. These results have a special relevance, 
taking into account that there are currently very few studies reporting on quality controls on 
specimens coming from different centers.  
Supplementary Figure 1 summarizes the role of the REDinREN Biobank Quality Management 
System to monitor, assess and identify the customer’s requirements, to analyze conforming or 
no-conforming results and to implement corrective or improvement actions.  
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CONCLUSION 
Typically, the collection of significant numbers of human biological samples and associated 
quality information involves a major effort in planning, construction, and finally operation, 
which consumes a significant amount of time and which slows down the development of 
experimental research. Hence, the promotion and implementation of biobanks, which facilitate 
the researcher’s access to quality samples (and associated data) with the proper ethical and legal 
safeguards for the donor, represent a major advance in shortening the time that normally elapses 
between research and the application of its results and in improving the effectiveness of 
research. The appropriate control that ensures the quality of the samples offered and their 
adequate long-term preservation in repositories is crucial. Maintenance and improvement of 
quality control are part of the REDinREN Biobank’s policy of ongoing improvement.  
The results presented in this study show that PBMC, DNA and RNA samples stored at 
REDinREN Biobank meet the necessary quality standards to be used in current biomedical 
research and that the methodology used complies with the requirements to ensure the long-term 
preservation of the specimens. 
 
ACKNOWLEDGMENTS  
This study was supported by grant Renal Research Network: FEDER funds ISCIII RETIC 
REDINREN RD12/0021/0006, by grant from Fondo de Investigaciones Sanitarias (FIS/ISCIII 
PI11/01630 and PI14/02075) to DRP and (FIS/ISCIII PI14/01939) to MRP, by grant from 
Universidad de Alcalá (CCG2015/BIO-034) to LCB and by Instituto de Investigaciones 
Sanitarias Reina Sofía (IRSIN) and Fundación Renal Iñigo Álvarez de Toledo (FRIAT).  
Vice-dean of Research at the Alcala University: Dr. María Luisa Marina Alegre. 
 
 
 
 
 
 21 
REFERENCES 
1. Le Page, C., Kobel, M., de Ladurantaye, M., et al. Specimen quality evaluation in canadian 
biobanks participating in the COEUR repository. Biopreserv Biobank 2013;11:83-93. 
2. Betsou, F., Barnes, R., Burke, T., et al. Human biospecimen research: Experimental protocol 
and quality control tools. Cancer Epidemiology Biomarkers & Prevention 2009;18:1017-25. 
3. Shabihkhani, M., Lucey, G,M., Wei, B., et al. The procurement, storage, and quality 
assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank 
settings. Clinical Biochemistry 2014;47:258-66. 
4. 2012 best practices for repositories collection, storage, retrieval, and distribution of biological 
materials for research. International Society for Biological and Environmental Repositories. 
Biopreserv Biobank 2012;10(2):79-161. 
5. Azimi-Nezhad, M., Lambert, D., Ottone, C., et al. Influence of pre-analytical variables on 
VEGF gene expression and circulating protein concentrations. Biopreserv Biobank 2012;5:454-
61.  
6. Wilfinger, W., Mackey, K,, Chomczynski, P. Effect of PH and ionic strength on the 
spectrophotometric assessment of nucleic acid purity. Biotechniques 1997;22:474-6, 478-81. 
7. Feezor, R,J., Baker, H,V., Mindrinos, M., et al. Whole blood and leukocyte RNA isolation for 
gene expression analyses. Physiol Genomics 2004;19(3):247-54. 
8. Fleige, S., Walf, V., Huch, S., et al. Comparison of relative mRNA quantification models and 
the impact of RNA integrity in quantitative real-time RT-PCR. Biotechnol Lett 
2006;28(19):1601-13. 
9. Shim, S,M,, Kim, J,H., Jung, S,E., et al. Multilaboratory assessment of variations in 
spectrophotometry-based DNA quantity and purity indexes. Biopreserv Biobank 2010;8(4):187-
92. 
10. Tang, W., Hu, Z., Muallem, H., Gulley, M.L. Quality assurance of RNA expression 
profiling in clinical laboratories. The Journal of molecular diagnostics: JMD 2012;14:1-11. 
 22 
11. Andreasson, A., Kiss, N.B., Juhlin, C.C., Hoog A. Long-term storage of endocrine tissues at 
-80 degrees C does not adversely affect RNA quality or overall histomorphology. Biopreserv 
Biobank 2013;11:366-70. 
12. Eikmans, M., Rekers, N,V., Anholts, J,D., et al. Blood cell mRNAs and microRNAs: 
optimized protocols for extraction and preservation. Blood 2013;121(11):e81-89 
13. Weinberg, A., Song, L.Y., Wilkening, C.L., et al. Optimization of storage and shipment of 
cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected 
individuals for Elispot assays. Journal of Immunological Methods 2010;363:42-50. 
14. Nederhand, R.J., Droog, S., Kluft, C., et al. Logistics and quality control for DNA sampling 
in large multicenter studies. J Thromb Haemost 2003;1:987-91. 
15. Kokkat, T.J., Patel, M.S., McGarvey, D., et al. Archived formalin-fixed paraffin-embedded 
(FFPE) blocks: A valuable underexploited resource for extraction of DNA, RNA, and protein. 
Biopreserv Biobank 2013;11:101-6. 
16. Micke, P., Ohshima, M., Tahmasebpoor, S., et al. Biobanking of fresh frozen tissue: RNA is 
stable in nonfixed surgical specimens. Lab Invest 2006;86:202-11. 
17. Betsou, F., Gunter, E., Clements, J., et al. Identification of evidence-based biospecimen 
quality-control tools: a report of the International Society for Biological and Environmental 
Repositories (ISBER) Biospecimen Science Working Group. J Mol Diagn. 2013;15(1):3-16 
18. Betsou, F., Bulla, A., Cho, S.Y., et al. Assays for Qualification and Quality Stratification of 
Clinical Biospecimens Used in Research: A Technical Report from the ISBER Biospecimen 
Science Working Group. Biopreserv Biobank. 2016. PMID 27046294 
19. Weinberg, A., Louzao, R., Mussi-Pinhata, M.M., et al. Quality assurance program for 
peripheral blood mononuclear cell cryopreservation. Clinical and Vaccine Immunology 
2007;14:1242-4. 
20. Ducar, C., Smith, D., Pinzon, C., et al. Benefits of a comprehensive quality program for 
cryopreserved PBMC covering 28 clinical trials sites utilizing an integrated, analytical Web-
based portal. Journal of Immunological Methods 2014;409:9-20.  
 23 
21. Coombs, R.W., Piwowar-Manning, E., Ducar, C., et al. Hanc HIV/AIDS network 
coordination. Procedimiento operativo estándar del procesamiento de PBMC entre redes. 2012. 
22. McKenna, K.C., Beatty, K.M., Vicetti, M,R., et al. Delayed processing of blood increases 
the frequency of activated CD11b + CD15 + granulocytes which inhibit T cell function. J 
Immunol Methods 2009;341:68–75 
23. Ley 14/2007, de 3 de julio, de investigación biomédica. Madrid- España: Boletín Oficial del 
Estado Nº 159; 2007. p. 28826- 48. 
24. Real decreto 1716/2011, de 18 de noviembre, por el que se establecen los requisitos básicos 
de autorización y funcionamiento de los biobancos con fines de investigación biomédica 
Madrid-España: Boletin Oficial del Estado Nº 290; 2011. p. 128434 - 54. 
25. Ley orgánica 15/1999, de 13 de diciembre, de protección de datos de carácter personal. 
Madrid- España: Boletín Oficial del Estado Nº 298; 1999. p. 43088. 
26. Real decreto 65/2006, de 30 de enero, por el que establecen requisitos para la importación y 
exportación de muestras biológicas. Madrid- España: Boletin Oficial del Estado Nº 32; 2006. p. 
4626- 36. 
27. Calleros, L., Cortes, M.A., Luengo, A., et al. Start-up of a clinical sample processing, 
storage and management platform: Organization and development of the REDinREN biobank. 
Nefrologia 2012;32:28-34. 
28. Cortes, M.A., Irrazabal, E., Garcia-Jerez, A., et al. Impact of implementing ISO 9001:2008 
standard on the Spanish renal research network biobank sample transfer process. Nefrologia 
2014;34:552-60. 
29. Ruitenberg, J.J., Mulder, C.B., Maino, V.C., et al. Vacutainer® CPT™ and Ficoll density 
gradient separation perform equivalently in maintaining the quality and function of PBMC from 
HIV seropositive blood samples. BMC Immunology 2006;7:11. 
30. Schroeder, A., Mueller, O., Stocker, S., et al. The RIN: An RNA integrity number for 
assigning integrity values to RNA measurements. BMC Molecular Biology 2006;7:3. 
31. Opitz, L., Salinas-Riester, G., Grade, M., et al. Impact of RNA degradation on gene 
expression profiling. BMC Medical Genomics 2010;3:36. 
 24 
32. Weinberg, A., Zhang, L., Brown, D., et al. Viability and functional activity of cryopreserved 
mononuclear cells. Clinical and Diagnostic Laboratory Immunology 2000;7:714-6. 
33. Sleasman,  J.W., Leon, B.H., Aleixo, L.F., et al. Immunomagnetic selection of purified 
monocyte and lymphocyte populations from peripheral blood mononuclear cells following 
cryopreservation. Clinical and Diagnostic Laboratory Immunology 1997;4:653-8. 
34. Reimann, K.A., Chernoff, M., Wilkening, C.L., et al. Preservation of lymphocyte 
immunophenotype and proliferative responses in cryopreserved peripheral blood mononuclear 
cells from human immunodeficiency virus type 1-infected donors: Implications for multicenter 
clinical trials. Clinical and Diagnostic Laboratory Immunology 2000;7:352-9. 
35. Hamot, G., Ammerlaan, W., Mathay, C., Method Validation for Automated Isolationof 
Viable Peripheral Blood Mononuclear Cells Biopreserv Biobank 2015:13(3):152-63 
36. Weinberg, A., Betensky, R.A., Zhang, L., et al. Effect of shipment, storage, anticoagulant, 
and cell separation on lymphocyte proliferation assays for human immunodeficiency virus-
infected patients. Clin Diagn Lab Immunol 1998;5:804–807 
37. Bull, M., Lee, D., Stucky, J., et al. Defining blood processing parameters for optimal 
detection of cryopreserved antigen-specific responses for HIV vaccine trials. J. Immunol. 
Methods 2007:322, 57.. 
38. Son, B.K., Roberts, R.L., Ank, B.J., et al. Effects of anticoagulant, serum, and temperature 
on the natural killer activity of human peripheral blood mononuclear cells stored overnight. Clin 
Diagn Lab Immunol 1996;3:260–264. 
39. Kierstead, L.S., Dubey, S., Meyer, B., et al, Enhanced rates and magnitude of immune 
responses detected against an HIV vaccine: effect of using an optimized process for isolating 
PBMC. AIDS Res. Hum. Retrovir. 2007:23, 86. 
40. Sarzotti-Kelsoe, M., Needham, L.K., Rountree, W., The Center for HIV/AIDS Vaccine 
Immunology (CHAVI) multi-site quality assurance program for cryopreserved human 
peripheral blood mononuclear cells. J Immunol Methods 2014:409:21-30.  
 
 
 25 
41. Imbeaud, S., Graudens, E., Boulanger, V., et al. Towards standardization of RNA quality 
assessment using user-independent classifiers of microcapillary electrophoresis traces. Nucleic 
Acids Res 2005;33(6):e56. 
42. Glasel JA. Validity of nucleic acid purities monitored by 260nm/280nm absorbance ratios. 
Biotechniques 1995;18:62-3. 
43. Manchester K. Use of UV methods for measurement of protein and nucleic acid 
concentrations. Biotechniques 1996;20:968. 
44. Sanchez, I., Remm, M., Frasquilho, S., How Severely Is DNA Quantification Hampered by 
RNA Co-extraction? Biopreserv Biobank. 2015:13(5):320-4.  
45. Jewell, S.D., Srinivasan, M., McCart, L.M., et al. Analysis of the molecular quality of 
human tissues an experience from the cooperative human tissue network. American Journal of 
Clinical Pathology. 2002;118:733-41. 
46. Jackson, D., Lewis, F., Taylor, G., et al. Tissue extraction of DNA and RNA and analysis by 
the polymerase chain reaction. Journal of Clinical Pathology. 1990;43:499-504. 
47. Bao, W.G., Zhang, X., Zhang, J.G., et al. Biobanking of fresh-frozen human colon tissues: 
Impact of tissue ex-vivo ischemia times and storage periods on RNA quality. Annals of Surgical 
Oncology 2013;20:1737-44. 
48. Hebels, D.G., Georgiadis, P., Keun, H.C., et al. Performance in omics analyses of blood 
samples in long-term storage: Opportunities for the exploitation of existing biobanks in 
environmental health research. Environmental Health Perspectives 2013;121:480-7. 
49. Junyent, M., Martínez, M., Borras, M., et al. Predicting cardiovascular disease morbidity 
and mortality in chronic kidney disease in Spain. The rationale and design of NEFRONA: a 
prospective, multicenter, observational cohort study. BMC Nephrology 2010;11-14. 
50. Betriu, A., Martinez-Alonso, M., Arcidiacono, M,V., et al. Prevalence of subclinical 
atheromatosis and associated risk factors in chronic kidney disease: the NEFRONA study. 
Nephrol Dial Transplant 2014;29:1415–1422. 
 26 
51. Arroyo, D., Betriu, A., Martinez-Alonso, M., et al. Observational multicenter study to 
evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney 
disease cohort: baseline data from the NEFRONA study. BMC Nephrology 2014;15-168. 
52. Martín, M., Valls, J., Betriu, A., et al. Association of serum phosphorus with subclinical 
atherosclerosis in chronic kidney disease. Sex makes a difference, Atherosclerosis 
2015;241:264-270. 
53. Gracia, M., Betriu, A., Martinez-Alonso, M., et al. Predictors of Subclinical Atheromatosis 
Progression over 2 Years in Patients with Different Stages of CKD. Clin J Am Soc Nephrol 
2016;11:287–296. 
54. Barrios, C., Pascual, J., Otero, S., et al. Diabetic nephropathy is an independent factor 
associated to severe subclinical atheromatous disease. Atherosclerosis 2015;242:37-44. 
55. Anguiano, L., Riera, M., Pascual, J., et al. Circulating Angiotensin-Converting Enzyme 2 
activity in patients with chronic kidney disease without previous history of cardiovascular 
disease. Nephrol Dial Transplant 2015;30(7):1176-85 
56. Fernandez-Laso, V., Sastre, C., Valdivielso, J,M., et al. Soluble TWEAK levels predict the 
presence of carotid atherosclerotic plaques in subjects free from clinical cardiovascular diseases 
Atherosclerosis  2015;239:358-363. 
57. Garcia-Jerez, A., Luengo, A., Carracedo, J., et al. Effect of uraemia on endothelial cell 
damage is mediated by the Integrin Linked Kinase pathway. The Journal of Physiology. 
2015;593:601-18 
 
 
 
 1 
 
 
 Mean concentration, ng/µl (SD) 
Concentration 
CV (%) 
Mean A260/A280 
ratio (SD) 
A260/A280 ratio 
CV (%) 
 Pool 1  86.75 (10.35) 11.93  2 (0.025) 1.25  
Pool 2  102.50 (9.82) 9.58   2.03 (0.02) 1.18  
 Pool 3  115.11 (8.30) 7.21  1.95 (0.01) 0.41  
 
 
Table 3: Quality control of the DNA extraction process. The table shows the mean ± SD 
values and coefficients of variation (CV) = (SD/mean)*100 of DNA concentration and the 
A260/A280 ratios, which were measured 5 times to date, from 3 different pools of PBMC, in 
accordance with our usual Protocol. 
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PROCESS PROBLEM CORRECTIVE ACTION  
Ficoll recovery of 
viable PBMC. 
Sample hemolysis Hemolyzed samples are excluded from 
quality control analysis.  
Formulation of acceptance criteria. 
Less than 80% viability No PBMC cryopreservation.  
Formulation of acceptance criteria. 
Nucleic acid 
extraction 
A260/A280 purity ratio  
deviates from acceptable 
criteria range. 
Vessels containing buffers are changed 
whenever an extraction is performed 
RNA Integrity 
Number (RIN) 
determination 
Samples with low RIN values, 
less than 7. 
They are marked.  
The researcher is notified when these 
samples are delivered. 
 
 
Table 4: Summary of problems and corrective actions to improve the process of sample 
management implemented in REDinREN Biobank. (PBMC) Peripheral Blood Mononuclear 
Cells. 
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DIFFICULTIES SOLUTION 
Different sample collection tubes 
(type and volume)  
Implementation of common Technical 
Instructions. 
Different health technical personnel 
to extract blood 
-Implementation of common Technical 
Instructions. 
-Training courses addressed to biobank 
technicians. 
Samples that are not suitably 
refrigerated 
Sending appropriate refrigeration equipment and 
instructions for use. 
Delay in sample delivery or receipt Coordinating the service of removal, shipment 
and receipt of the sample. 
Broken tubes Providing all centers with a sample cylinder for 
protection during shipping. 
Problems caused by couriers’ 
delays or failure to collect the 
specimens 
Changing the courier company and setting a new 
schedule. 
 
 
Table 5: Summary of difficulties and solutions implemented in REDinREN Biobank 
related to multisite collection of samples. All samples were shipped to a central site using 
common Technical Instructions. 
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FIGURE LEGENDS 
Figure 1: Quality of PBMC (Peripheral Blood Mononuclear cells) isolation from 
peripheral blood. Analysis of the performance of the PBMC isolation technique expressed as 
the number of viable cells obtained per milliliter of whole blood, associated with their year of 
isolation. Total number of specimens processed: 2,724. Plots represent the mean ± SD values 
for each year. 
Figure 2: Viability of Peripheral Blood Mononuclear cells (PBMC) cryopreserved in 10% 
DMSO.  Viability of cells thawed and cultured for 14 days, measured by Trypan Blue exclusion 
test from Day 0 (thawing day) to Day 14. The % of live cells from ten independently thawed 
samples was achieved. Dots represent individual values from all the samples studied. Bars 
represent the median and interquartile range values for each day. The horizontal line represents 
80% of cell viability. 
Figure 3: Quality of DNA isolated from PBMC by automated QIAcube (Qiagen) system. 
Panel A: isolated DNA ratio of absorbance at 260nm/280nm (A260/A280) of the 2,328 samples 
analyzed associated with their year of storage. Plots represent the mean ± SD values for each 
year. Panel B: representative image of gel agarose electroforesis of 2 samples of genomic DNA 
in the following three assumptions: CT (untreated DNA control), 1 (DNA treated with DNAse) 
and 2 (DNA after being heated at 100º C for 15 minutes). Panel C: representative image of a 
very good DNA sample assessed by PCR amplification of β-globulin gene fragments that 
presents four PCR amplified products in four independent PCR reactions. Panel D and E: Ct 
values of 30 DNA samples associated with their year of storage, obtained by qPCR 
amplification of endogenous β-actin (D) and GAPDH (E) genes. Dots represent individual 
values from all the samples studied.  Bars represent the median plus interquartile range values 
for each year. 
Figure 4: Quality of RNA isolated from peripheral blood by PAXgene system. Panel A: 
isolated RNA ratio of absorbance at 260nm/280nm (A260/A280) of the 78 samples analyzed 
associated with their year of storage. Panel B: RIN (RNA Integrity Number) values obtained for 
 2 
96 samples associated with their year of storage. On the right panel, an electropherogram 
representative of a sample of total RNA with a good RIN value of 9.9 (upper panel) and a poor 
RIN value of 5.7 (bottom panel) with no distinct bands visible, can be observed. The horizontal 
line represents a RIN value of 7. Panel C and D: Ct values of 30 RNA samples associated with 
their year of storage, obtained by RT-qPCR amplification of endogenous β-actin (C) and 
GAPDH (D) genes. Panel A to D: dots represent individual values from all the samples studied. 
Bars represent the median plus interquartile range values for each year.   
 
 
 
 
 






